Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Purchased by State Street Corp

State Street Corp increased its position in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 35.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 286,046 shares of the company’s stock after purchasing an additional 74,300 shares during the quarter. State Street Corp’s holdings in Prelude Therapeutics were worth $592,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. Walleye Capital LLC grew its holdings in shares of Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock worth $172,000 after buying an additional 67,946 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Prelude Therapeutics by 2.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock valued at $1,990,000 after acquiring an additional 14,226 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in Prelude Therapeutics by 32.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock valued at $133,000 after acquiring an additional 15,682 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after purchasing an additional 14,769 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Prelude Therapeutics by 885.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock worth $362,000 after purchasing an additional 157,218 shares during the last quarter. 79.72% of the stock is owned by institutional investors and hedge funds.

Prelude Therapeutics Stock Performance

PRLD stock opened at $1.39 on Friday. Prelude Therapeutics Incorporated has a one year low of $0.80 and a one year high of $6.80. The firm has a market cap of $76.50 million, a PE ratio of -0.78 and a beta of 1.49. The firm’s 50 day moving average price is $1.11 and its 200-day moving average price is $3.01.

Prelude Therapeutics (NASDAQ:PRLD) last posted its earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. The business had revenue of $3.00 million during the quarter. Equities research analysts predict that Prelude Therapeutics Incorporated will post -1.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PRLD. JMP Securities reiterated a “market outperform” rating and set a $4.00 price objective (down previously from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a report on Friday, November 8th.

Insider Buying and Selling at Prelude Therapeutics

In other news, insider Andrew Combs bought 60,000 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $1.37 per share, with a total value of $82,200.00. Following the completion of the transaction, the insider now directly owns 377,623 shares in the company, valued at $517,343.51. This trade represents a 18.89 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Krishna Vaddi purchased 100,000 shares of the stock in a transaction dated Wednesday, December 18th. The shares were purchased at an average price of $0.93 per share, with a total value of $93,000.00. Following the completion of the transaction, the chief executive officer now owns 1,167,275 shares of the company’s stock, valued at approximately $1,085,565.75. This trade represents a 9.37 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 198,075 shares of company stock valued at $213,486 over the last 90 days. 62.80% of the stock is owned by insiders.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.